Sodium Selenate Treatment for Temporal Lobe Epilepsy

What is the study?

- This research project is looking at whether the trial drug, sodium selenate decreases seizure activity in people with chronic drug-resistant temporal lobe epilepsy (TLE).
- Up to **124** participants in **VIC, NSW, QLD**, and **WA** will take part in this research project overall
- Participants are randomly assigned to one of two groups. One group will receive the study drug, sodium selenate, and the other group will receive a placebo. The study drug (or placebo) is taken three times a day

If i take part, what will i need to do?

- Attend appointments at the study doctor's clinic up to eight times over 12 months
- Take the study drug (or placebo) three times a day for 26 weeks
- Maintain a diary card (recording any side effects, medication changes, and seizure activity)

What assessments are involved?

- **3 x 24-hour ambulatory EEG recordings** (1 at the beginning, 1 at the middle, and 1 at the completion of the study) done at home.
- Physical and neurological examinations
- Blood tests
- Cognitive tests and questionnaires

What are the potential benefits and risks of being in the study?

- Access to a potential treatment for TLE
- The study may provide a better understanding of TLE to improve future treatment

Possible side effects of the drug?	• Nail changes • Fatigue • Hair loss • Muscle pain • Headache • Diarrhoea

Please note it is possible that not all applicants will be eligible or selected to participate in this study.

Contact

Name: Tatevik Mazmanyan
Email: tatevik.mazmanyan@monash.edu
Phone: 03 9903 0121